Barkus, E and Lewis, S (2008) Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine 38, 1267–1276.
Barkus, EJ, Stirling, J, Hopkins, RS and Lewis, S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 175–178.
Bhattacharyya, S, Atakan, Z, Martin-Santos, R, Crippa, Ja, Kambeitz, J, Prata, D et al. (2012) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry 17, 1152–1155.
Bianconi, F, Bonomo, M, Marconi, A, Kolliakou, A, Stilo, SA, Iyegbe, C et al. (2016) Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychological Medicine 46, 995–1003.
Birnbaum, ML, Cleary, SD, Ramsay Wan, C, Pauselli, L and Compton, MT (2017) Factor structure of the Cannabis Experiences Questionnaire in a first-episode psychosis sample. Early Intervention in Psychiatry, 1–7. doi: 10.1111/eip.12509. [Epub ahead of print].
Braun, V and Clarke, V (2006) Using thematic analysis in psychology. Qualitative Research in Psychology 3, 77–101.
Degenhardt, L and Hall, W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet 379, 55–70.
Di Forti, M, Iyegbe, C, Sallis, H, Kolliakou, A, Falcone, MA, Paparelli, A et al. (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811–816.
Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR et al. (2009) High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488–491.
D'Souza, DC, Abi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594–608.
Frisher, M, Crome, I, Martino, O and Croft, P (2009) Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophrenia Research 113, 123–128.
Gage, SH, Hickman, M and Zammit, S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biological Psychiatry 79, 549–556.
Grant, JD, Scherrer, JF, Lyons, MJ, Tsuang, M, True, WR and Bucholz, KK (2005) Subjective reactions to cocaine and marijuana are associated with abuse and dependence. Addictive Behaviors 30, 1574–1586.
Henquet, C, Rosa, A, Krabbendam, L, Papiol, S, Fananás, L, Drukker, M et al. (2006) An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748–2757.
Hill, M (2015) Perspective: be clear about the real risks. Nature 525, S14–S14.
Kandel, DB and Logan, JA (1984) Patterns of drug-use from adolescence to young adulthood. 1. Periods of risk for initiation, continued use, and discontinuation. American Journal of Public Health 74, 660–666.
Kandel, DB and Raveis, VH (1989) Cessation of illicit drug use in young adulthood. Archives of General Psychiatry 46, 109–116.
Kuepper, R, van Os, J, Lieb, R, Wittchen, H-U, Höfler, M and Henquet, C (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (Clinical Research Ed.) 342, d738.
Le Strat, Y, Ramoz, N, Horwood, J, Falissard, B, Hassler, C, Romo, L et al. (2009) First positive reactions to cannabis constitute a priority risk factor for cannabis dependence. Addiction 104, 1710–1717.
Little, MA, Spruijt-Metz, D, Pokhrel, P, Sun, P, Ann Rohrbach, L and Sussman, S (2013) Predicting self-initiated marijuana use cessation among youth at continuation high schools. Frontiers in Psychiatry 4, 1–7.
Lyons, MJ, Toomey, R, Meyer, JM, Green, AI, Eisen, SA, Goldberg, J et al. (1997) How do genes influence marijuana use? The role of subjective effects. Addiction 92, 409–417.
Marconi, A, Di Forti, M, Lewis, CM, Murray, RM and Vassos, E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin 42, 1262–1269.
Mason, O, Morgan, CJA, Dhiman, SK, Patel, A, Parti, N and Curran, HV (2009) Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychological Medicine 39, 951–956.
Moore, THM, Zammit, S, Lingford-Hughes, A, Barnes, TRE, Jones, PB, Burke, M et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet 370, 319–328.
Kahn, RS, Linszen, DH, van OS, J, Wiersma, D, Bruggeman, R, Cahn, W, de Hann, L, Krabbendam, L, Myin-Germeys, I; Genetic Risk and outcome of Psychosis (Group) Investigators (2011) Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Archives of General Psychiatry 68, 138–147.
Quinn, CA, Wilson, H, Cockshaw, W, Barkus, E and Hides, L (2017) Development and validation of the cannabis experiences questionnaire – intoxication effects checklist (CEQ-I) short form. Schizophrenia Research 189, 91–96.
Scherrer, JF, Grant, JD, Duncan, AE, Sartor, CE, Haber, JR, Jacob, T et al. (2009) Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. Drug and Alcohol Dependence 105, 76–82.
Schoeler, T, Monk, A, Sami, MB, Klamerus, E, Foglia, E, Brown, R et al. (2016 a) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet Psychiatry 3, 215–225.
Schoeler, T, Petros, N, Di Forti, M, Klamerus, E, Foglia, E, Ajnakina, O et al. (2016 b) Effects of continuation, frequency and type of cannabis use on relapse in the first two years following onset of psychosis – an observational study. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license, Lancet Psychiatry 366, 1–7.
Schoeler, T, Petros, N, Di Forti, M, Pingault, J-B, Klamerus, E, Foglia, E et al. (2016 c) Association between continued cannabis use and risk of relapse in first-episode psychosis. JAMA Psychiatry 35, 557–574.
Stirling, J, Barkus, EJ, Nabosi, L, Irshad, S, Roemer, G, Schreudergoidheijt, B et al. (2008) Cannabis-induced psychotic-like experiences are predicted by high schizotypy: confirmation of preliminary results in a large cohort. Psychopathology 41, 371–378.
Thomas, H (1996) A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 42, 201–207.
Valmaggia, LR, Day, FL, Jones, C, Bissoli, S, Pugh, C, Hall, D et al. (2014) Cannabis use and transition to psychosis in people at ultra-high risk. Psychological Medicine 44, 2503–2512.
van den Bree, MBM, Pickworth, WB (2005) Risk factors predicting changes in marijuana involvement in teenagers. Archives of General Psychiatry 62, 311.
van Gastel, WA, Vreeker, A, Schubart, CD, MacCabe, JH, Kahn, RS and Boks, MPM (2014) Change in cannabis use in the general population: a longitudinal study on the impact on psychotic experiences. Schizophrenia Research 157, 266–270.
von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC and Vandenbroucke, JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet 370, 1453–1457.
Zeiger, JS, Haberstick, BC, Corley, RP, Ehringer, MA, Crowley, TJ, Hewitt, JK et al. (2010) Subjective effects to marijuana associated with marijuana use in community and clinical subjects. Drug and Alcohol Dependence 109, 161–166.